中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

100 records (took 0.021 seconds)

    New peptide compounds, e.g. aza-heterocyclic substituted beta-alanine derivatives, are integrin receptor antagonists useful e.g. for treating atherosclerosis, cancer, osteoporosis, hypertension or inflammation
    70.
    发明专利
    New peptide compounds, e.g. aza-heterocyclic substituted beta-alanine derivatives, are integrin receptor antagonists useful e.g. for treating atherosclerosis, cancer, osteoporosis, hypertension or inflammation 未知

    公开(公告)号：DE19919218A1

    公开(公告)日：2000-11-02

    申请号：DE19919218

    申请日：1999-04-28

    Applicant: BASF AG

    Inventor： KLING ANDREAS ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GENESTE HERVE ,  SUBKOWSKI THOMAS ,  ZECHEL JOHANN-CHRISTIAN ,  DAX CLAUDIA ISABELLA

    IPC: C07C275/42 ,  C07D263/34 ,  C07D277/48 ,  C07D277/56 ,  C07D307/68 ,  C07D333/38 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07K5/078 ,  A61K38/05

    Abstract: Peptide compounds (I) are new. Peptide derivatives of formula A-E-G-L (I) and their salts, prodrugs, enantiomers, diastereomers and tautomers are new. L = -N(R4)-CHR3-(CHR2)a-T; a = 0 or 1; T = COOH or group hydrolyzable to COOH; R2 = H, NHSO2R21, NHCOR21 or NHCOOR22; R21 = 1-6C alkyl, 3-6C cycloalkyl, (1-4C) alkyl-(3-6C) cycloalkyl, 5-12C bicycloalkyl or 6-18C tricycloalkyl (all optionally substituted (os)); or aryl, aralkyl, alkylheteroaryl or 3-6 membered (un)saturated or aromatic heterocycle (all os by 1-3 groups, two of which may together form a fused (un)saturated or aromatic heterocycle, itself os and optionally carrying a fused os (un)saturated or aromatic ring); R22 = alkyl, aryl, or alkylaryl (all os); R3 = H or -(CH2)b-(X)c-R31; b = 0-3; c = 0 or 1; X = SO2, S, O, CO, NHSO2, OCO, COO, NHCO, CONH, CON(R31), N(R31)CO, SO2NH, SO2N(R31) or N(R31)SO2; R31 = H or OH; 1-6C alkyl, alkoxy, arylalkoxy or aryloxy (all os); primary and optionally secondary or tertiary substituted amino; 2-6C alkenyl or 2-6C alkynyl (both os by 1-4C alkyl or aryl); 5-12C bicycloalkyl or 6-18C tricycloalkyl; or 3-6 membered (un)saturated heterocycle, 3-8C cycloalkyl, aryl or heteroaryl (all os by 1-3 groups, two of which may together form a fused (un)saturated or aromatic carbocycle or heterocycle, itself os and optionally carrying a fused os (un)saturated or aromatic ring); R4 = 1-4C alkyl, 3-6C alkenyl, 3-6C alkynyl or 3-6C cycloalkyl (all os); G = -N(R6)-CH((CH2)dR5)-CO-; d = 0-2;l R5 = as R31; or the side-chain of a natural aminoacid; R6 = H or as R4; E = -(NH)g-(CH2)t-Q-(CH2)e-CO-; e = 0-2; f, g = 0 or 1; Q = os heteroarylene (where two substituents may together form a fused (un)saturated or aromatic carbocycle or heterocycle, itself os and optionally carrying a fused os (un)saturated or aromatic ring); A = R10R11N-C(O)-, R10R11N-C(S)-, R10R11N-C(O)-, R12OC(O)- or R14N-C(=NR13)-; 2-pyridinyl, 2-pyrimidinyl or 4-pyrimidinyl, all substituted by R16 and R17; a diaza-heterocyclic group of formula (A1); a fused imidazole group of formula (A2); 3,4-dihydro-5H-1,3-thiazin-2-yl; uracil-6-yl; 1-aza-cyclopent-1-en-2-yl; 1-aza-cyclohex-1-en-2-yl; 1-aza-cyclohept-1-en-2-yl; or 5-oxo-4,5-dihydro-imidazol-2-yl; R10, R11 = H or -(CH2)h(X)i-R101; or NR10R11 = 3-8 membered os (un)saturated or aromatic heterocycle (optionally containing two further O, N or heteroatoms); h = 0-3; i = 0 or 1; R101 = as R31 but not H; R12 = alkyl, alkylaryl, 3-6C cycloalkyl, (1-4C) alkyl-(3-6C) cycloalkyl or aryl (all os); R13 = H, OH, CN or CONH2; or 1-4C alkyl, 1-4C alkoxy, -OCO-(1-4C) alkyl, alkylaryl, -O-alkylaryl, -OCO-aryl, -OCO-alkylaryl or -OCO-allyl (all os); R14 = H or (all os) 1-4C alkyl, -COO-(1-4C) alkyl, alkylaryl, -COO-alkylaryl, -COO-allyl, -CO-(1-4C) alkyl, -CO-alkylaryl or -CO-allyl; R15 = H or (all os) 1-4C alkyl, aryl or alkylaryl; R16, R17 = NH2, halo or (all os) 1-4C alkyl, 1-4C alkoxy or aryl; V = CH2CH2, CH=CH, 1,2-cyclohexylene, 1,2-cyclohex-1-enylene, (CH2)3 or CH2C(Me)2CH2; Z1-Z4 = CH, C(Me), C(Cl) or N; heterocycles contain 1-3 of O, S and/or N.

Patent Agency Ranking